Cargando…

P1121: TAKEAIM LYMPHOMA- AN OPEN-LABEL, DOSE ESCALATION AND EXPANSION TRIAL OF EMAVUSERTIB (CA-4948) IN COMBINATION WITH IBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES

Detalles Bibliográficos
Autores principales: Joffe, E., Nowakowski, G., Tun, H., Rosenthal, A., Lunning, M., Ramchandren, R., Li, C.-C., Zhou, L., Martinez, E., von Roemeling, R., Earhart, R., McMahon, M., Isufi, I., Leslie, L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430533/
http://dx.doi.org/10.1097/01.HS9.0000847352.16311.ea